Tracers / [68Ga]Ga-P16-093
[68Ga]Ga-P16-093
Also written as [68Ga]Ga-P16-093; [Ga-68]Ga-P16-093
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- Phase 2 clinical trial
- Syntheses indexed
- 1
What it is
- Compound class
- Small molecule PSMA-targeting PET radioligand (O-(carboxymethyl)-L-tyrosine scaffold with HBED-CC chelator)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 35349040
- Clinical application
- Prostate cancer patients, including newly diagnosed primary disease and biochemical recurrence PMID 41366119
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 42418373 2026 J Med Chem |
Need this precursor?We can point you to suppliers for [68Ga]Ga-P16-093, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-P16-093.
Get in touchNotes
Added from reverse module search (stage 6); 3 article(s) with Ga-68.